Q-omics provides the consensus-scored RPS18P6 profile across patient tissues and cancer cell-line models. RPS18P6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS18P6 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPS18P6 RNA expression shows 5,366 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight ACC, THCA, and READ as cancer lineages where RPS18P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS18P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS18P6 survival associations across molecular data types. RPS18P6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS18P6 RNA expression–survival associations across cancer types. High RPS18P6 expression shows unfavorable associations in ACC, LIHC, OV, KICH, THYM and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS18P6 RNA expression.
This table summarizes RPS18P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS18P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS18P6 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC and LUAD. The THCA box plot shows higher RPS18P6 RNA expression in normal versus tumor tissue (log2 FC = −0.163, t-test p < 0.001).
This table shows molecular features associated with RPS18P6 in patient tissues and cancer cell lines. In patient samples, RPS18P6 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
